Serum samples from 128 wild vicuñe; as (Vicugna vicugna) were tested for antibodies (Ab) to rotavirus (RV), bovine parainfluenza virus 3 (BPIV-3), bovine herpesvirus-1 (BHV-1), bovine viral diarrhea virus (BVDV-1), foot-and-mouth disease virus (FMDV), bluetongue virus (BTV), equine herpesvirus-1 (EHV-1), and influenza A virus equine (EIV). Samples were collected in Cieneguillas Province of Jujuy, in northern Argentina. Feces from 44 vicuñe; as were also collected to investigate RV shedding. Llamas (Lama glama) and domestic cattle (Bos taurus) from the area studied also were tested for antibodies to these viruses. Antibodies against RV (100%) and BPIV-3 (37%) were detected in the vicuñe; as sampled. No RV antigen was detected in any of the fecal samples tested. One vicuñe; a was positive for Ab to BHV-1 (0.8%) and another for BVDV-1 (0.8%). The Ab prevalences detected in llamas were: 100% (16/16) for RV, 47% (8/17) for BPIV-3, 17.6% (3/17) for BHV-1, and 5.9% (1/17) for BVDV-1. However, domestic cattle had high antibody prevalences for RV and BPIV-3, 100% (13/13) and 73% (11/15), respectively, but were negative for Ab to BHV-1 and BVDV. No antibodies against FMDV, BTV, EHV-1, or EIV were detected in wild vicuñe; as or domestic species. Because no data of viral circulation on wild vicuñe; as are available, this report represents the first evidence of viral infection in wild vicuñe; as from the Argentinean Andean Puna.
You have requested a machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Neither BioOne nor the owners and publishers of the content make, and they explicitly disclaim, any express or implied representations or warranties of any kind, including, without limitation, representations and warranties as to the functionality of the translation feature or the accuracy or completeness of the translations.
Translations are not retained in our system. Your use of this feature and the translations is subject to all use restrictions contained in the Terms and Conditions of Use of the BioOne website.
Vol. 46 • No. 2